Patents Represented by Attorney, Agent or Law Firm John T. Prince
  • Patent number: 6924106
    Abstract: The present invention primarily relates to a DNA fragment which is obtainable from the gene cluster responsible for rifamycin biosynthesis within the genome of Amycolatopsis mediterranei, and comprises at least one gene or a part of a gene which codes for a polypeptide which is directly or indirectly involved in the biosynthesis of rifamycin, and to a method for preparing said DNA fragment. The present invention furthermore relates to recombinant DNA molecules which comprise one of the DNA fragments according to the invention, and to the plasmids and vectors derived therefrom. Host organisms transformed with said plasmid or vector DNA are likewise embraced.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: August 2, 2005
    Assignee: Novartis AG
    Inventors: Thomas Schupp, Christiane Toupet, Nathalie Engel
  • Patent number: 6833255
    Abstract: The invention provides Drosophila melanogaster p70S6K, as well as nucleic acids encoding this kinase. The sequence of Drosophila p70S6K and the gene encoding it are represented in SEQ ID No. 2 and 1 respectively. The invention moreover provides mutated forms of Drosophila p70S6K, including constitutively active and dominant negative forms thereof, which are useful in the study of p70S6K activity. Furthermore, the invention provides expression systems which produce Drosophila p70S6K in Drosophila and other organisms, and in particular systems in which expression of Drosophila p70S6K has been modulated so as to facilitate the study of its activity.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: December 21, 2004
    Assignee: Novartis, AG
    Inventors: Mary Stewart, Sara Kozma, George Thomas
  • Patent number: 6660526
    Abstract: A fluoroionophore for the fluorescent detection of potassium ions.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: December 9, 2003
    Assignees: Bayer Corporation, Worcester Polytechnic Institute
    Inventors: John S. Benco, W. Grant McGimpsey, Hubert Nienaber
  • Patent number: 6183735
    Abstract: The invention features immortalized retina-derived (retinal endothelial or retinal epithelial pigmentary) cell lines capable of being implanted in the retina and of carrying a therapeutic substance to the eye and to the central nervous system. Such lines can also be used as a model for studying blood central nervous system interfaces. These lines are derived from primary retinal cultures selected from the group consisting of primary retinal endothelial cells and primary retinal epithelial cells, comprise a nucleic acid fragment containing at least one immortalizing fragment of a heat-sensitive viral oncogene, which nucleic fragment is optionally associated with at least one selection gene, and have the morphological characteristics and at least the expression characteristics of the surface antigens of corresponding primary cultures.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: February 6, 2001
    Assignee: Neurotech, SA
    Inventors: John Greenwood, Peter Adamson, Raymond Lund
  • Patent number: 6179826
    Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12).
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: January 30, 2001
    Assignee: Brown University Research Foundation
    Inventors: Patrick Aebischer, Moses Goddard, John G. Moldauer, Paul J. Mulhauser, Anne M. Rathbun, Paul R. Sanberg, Alfred V. Vasconcellos, Nicholas F. Warner
  • Patent number: 6033906
    Abstract: Method for producing a population of mammalian glial cells comprising contacting at least one mammalian neural stem cell with a culture medium containing a neuregulin and detecting the differentiation of stem cell to a population of glial cells.
    Type: Grant
    Filed: May 6, 1995
    Date of Patent: March 7, 2000
    Assignee: California Institute of Technology
    Inventor: David J. Anderson
  • Patent number: 5968829
    Abstract: Isolation, characterization, proliferation, differentiation and transplantation of mammalian neural stem cells is disclosed.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 19, 1999
    Assignee: Cytotherapeutics, Inc.
    Inventor: Melissa Carpenter